A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions
Open Access
- 3 November 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 2 (1) , 192-205
Abstract
We show for the first time that PD-1 is palmitoylated, identify DHHC9 as the predominant enzyme for its palmitoylation, and reveal the molecular mechanisms underlying its effects on PD-1 stability and functions. Importantly, we also designed PD1-PALM, a competitive inhibitor of PD-1 palmitoylation, and this first-in-class molecule may inspire the development of new checkpoint inhibitors.Keywords
Funding Information
- National Natural Science Foundation of China (82030104)
- National Natural Science Foundation of China (81874050)
- National Natural Science Foundation of China (81572326)
- National Natural Science Foundation of China (81322036)
- National Natural Science Foundation of China (81421001)
- National Natural Science Foundation of China (81702969)
- National Natural Science Foundation of China (81530072)
- National Natural Science Foundation of China (81830081)
- National Natural Science Foundation of China (31871009)
- National Natural Science Foundation of China (81772506)
- National Natural Science Foundation of China (21335002)
- National Key Research and Development Program of China (2016YFC0906000)
- National Key Research and Development Program of China (2016YFC0906002)
- Scientific and Innovative Action Plan of Shanghai (20JC1410700)
- Natural Science Foundation of Shanghai Municipality (18ZR1402800)
- Fudan University (JIH1340050)
This publication has 26 references indexed in Scilit:
- Methodology for Detecting Protein Palmitoylation2020
- Palmitoylation as a Signal for Delivery2020
- FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cellsNature, 2018
- Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial ImmunotherapyFrontiers in Immunology, 2018
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionFrontiers in Pharmacology, 2018
- Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1Hepatology, 2017
- Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplificationLaboratory Investigation, 2017
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor GrowthCell, 2015
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJournal of Experimental Medicine, 2010